T細胞の認識する癌抗原同定と癌免疫治療

概要

論文の詳細を見る
We have continuously attempted to isolate T-cell defined tumor antigens in order to eradicate ancers in vivo. First, we established tumor cell lines from a cancer patient and, subsequently, T-cells from the ame patient that could recognize autologous tumor cells. To date, we have successfully established and analyzed over a dozen systems in such autologous settings. Through this analysis, we have identified two gastric cancer antigens and a squamous cell cancer antigen. Moreover, by “reverse immunological” approaches, we have identified three cancer-specific T-cell defined antigenic peptides from recoverin, SYT-SSX, and survivin. Based on the identification of antigens, we have begun phase-I clinical trials of an SYT-SSX-derived peptide for advanced synovial sarcoma patients in the Department of Orthopedics and a survivin-derived peptide for breast or colon cancer patients in the Department of Surgery in our university hospital.
札幌医科大学の論文
2002-12-01